Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents.
about
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysisThe RNA Splicing Response to DNA DamageVascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis?Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model.Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.Vascular Endothelial Growth Factor-111 (VEGF-111) and tendon healing: preliminary results in a rat model of tendon injuryThe anti-angiogenic isoforms of VEGF in health and disease.Molecular diversity of VEGF-A as a regulator of its biological activity.Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing.Effects of mild cold shock (25°C) followed by warming up at 37°C on the cellular stress response.VEGF111: new insights in tissue invasion.Isoform 165 of vascular endothelial growth factor in collagen matrix improves ovine cryopreserved ovarian tissue revascularisation after xenotransplantation in miceInfluence of mouse strain on ovarian tissue recovery after engraftment with angiogenic factor.VEGF spliced variants: possible role of anti-angiogenesis therapy.Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosisVEGFA family isoforms regulate spermatogonial stem cell homeostasis in vivoVEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery.Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMDA review of the evolution of viviparity in squamate reptiles: the past, present and future role of molecular biology and genomics.New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation.Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.A lean and mean VEGF for cancer cells.VEGF-A121a binding to Neuropilins - A concept revisited.Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration.Expression of VEGF 111 and other VEGF-A variants in the rat uterus is correlated with stage of pregnancy.Enhanced expression of bioactive recombinant VEGF-111 with insertion of intronic sequence in mammalian cell lines.Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.Unusual angiogenic factor plays a role in lizard pregnancy but is not unique to viviparity.Evolution of the VEGF-Regulated Vascular Network from a Neural Guidance SystemHistological evaluation of the effect of VEGF on auto-transplanted mouse ovaries
P2860
Q21202775-53B06FFD-AA5C-415D-9266-88EFC293DEABQ26777046-B6DCC00D-380C-40FE-AA4F-C4BCF6D15608Q26777347-543EB7A3-03E0-46AA-898C-4CA6A0663E8BQ27000351-A2B1F633-0A06-459A-B241-7C9AC98DCB08Q33649673-C409C3C0-5E62-4FA5-83B7-970D313B1092Q33689582-A1A41F95-608B-4275-BD54-7B2A56BC6E71Q33727382-48E639B4-73B8-4952-B591-FE4DFB9C6A62Q33901839-80A7A624-4156-4631-A8CE-764660173103Q34089123-30CAE694-B6F0-458E-843B-76C9BE0D3043Q34712017-997DD0E5-182D-46CC-A9A0-FDD18A10CC3DQ34920889-6C74E10A-E149-4554-9744-621A2A480F2CQ34999113-BF29231B-0506-40BA-AD7D-B9EBDE49E366Q35206542-5C7131AA-6878-493D-853C-D07956390ECEQ35225712-3EFF1FD2-A9A5-48B7-AEE5-FDEEA033839EQ35369677-6D80717A-1A64-4AF4-8818-667F97BEBBFFQ35442986-90B9E1F2-08CE-42A3-8BEF-AFF40638AC80Q35744566-18DB713F-AC0D-444F-B9F4-A2AFC97E05E1Q35780939-271799EC-351C-4966-AC99-36A0690D35ADQ36186814-54D45E42-D033-4B5F-9061-27345958953BQ37166978-4900CD89-62DA-45CE-8652-ED42BFD8C818Q37875795-C89C8B29-E5CE-4CF6-9E9B-0F9E09E0F673Q38319139-B8845F06-19CB-41CF-AEC4-B257386B95A8Q39426973-CDBF0B17-C72F-4966-8273-8DC7A5F4C392Q46856056-BCEDE09A-C9C5-4A65-9A24-0ECE30DCDDBFQ47388605-54BEB80E-F4ED-4FB7-9019-86B19C6F85B8Q51022833-8BE16A47-2253-4666-AAE4-CA4F58E60880Q51410876-9C112C55-4400-470D-B892-486A08E7EC65Q51743839-BA461529-9E27-40A4-852B-D126DE3C911AQ52717006-D3F40AED-5776-4D3E-8B55-23078B0B76D7Q53591361-757A5A82-CF4A-4B70-95F4-8FD5A7282BDDQ56487095-7CC461D6-0AE3-4ED4-9DDE-E53128398C07Q57430305-5EE6C53F-9BD5-40F2-B4E7-428E5F92CEAE
P2860
Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Newly identified biologically ...... s induced by genotoxic agents.
@ast
Newly identified biologically ...... s induced by genotoxic agents.
@en
type
label
Newly identified biologically ...... s induced by genotoxic agents.
@ast
Newly identified biologically ...... s induced by genotoxic agents.
@en
prefLabel
Newly identified biologically ...... s induced by genotoxic agents.
@ast
Newly identified biologically ...... s induced by genotoxic agents.
@en
P2093
P2860
P50
P356
P1476
Newly identified biologically ...... is induced by genotoxic agents
@en
P2093
Alain C Colige
Betty V Nusgens
Charles A Lambert
Charles M Lapière
Christophe F Deroanne
Frédéric Kesteloot
Pierre Mineur
Stefan Vöö
Yvette Habraken
P2860
P304
P356
10.1083/JCB.200703052
P407
P577
2007-12-01T00:00:00Z